vs
Side-by-side financial comparison of FrontView REIT, Inc. (FVR) and SCYNEXIS INC (SCYX). Click either name above to swap in a different company.
SCYNEXIS INC is the larger business by last-quarter revenue ($18.6M vs $16.5M, roughly 1.1× FrontView REIT, Inc.). SCYNEXIS INC runs the higher net margin — 65.7% vs -24.9%, a 90.6% gap on every dollar of revenue.
SCYNEXIS Inc. is a biotechnology company focused on developing innovative antifungal therapies to address unmet medical needs for difficult-to-treat fungal infections. It targets hospital and specialty care markets, with key product candidates serving immunocompromised patients and other high-risk groups.
FVR vs SCYX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.5M | $18.6M |
| Net Profit | $-4.1M | $12.3M |
| Gross Margin | — | — |
| Operating Margin | — | 56.3% |
| Net Margin | -24.9% | 65.7% |
| Revenue YoY | — | 1808.5% |
| Net Profit YoY | — | 376.5% |
| EPS (diluted) | $-0.19 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.5M | $18.6M | ||
| Q3 25 | $16.8M | $334.0K | ||
| Q2 25 | $17.6M | $1.4M | ||
| Q1 25 | $16.2M | $257.0K | ||
| Q4 24 | — | $977.0K | ||
| Q3 24 | $14.5M | $660.0K | ||
| Q2 24 | — | $736.0K | ||
| Q1 24 | — | $1.4M |
| Q4 25 | $-4.1M | $12.3M | ||
| Q3 25 | $4.0M | $-8.6M | ||
| Q2 25 | $-2.9M | $-6.9M | ||
| Q1 25 | $-833.0K | $-5.4M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-2.4M | $-2.8M | ||
| Q2 24 | — | $-14.5M | ||
| Q1 24 | — | $411.0K |
| Q4 25 | — | 56.3% | ||
| Q3 25 | — | -2516.5% | ||
| Q2 25 | — | -701.0% | ||
| Q1 25 | — | -3350.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | -1563.6% | ||
| Q2 24 | — | -1255.0% | ||
| Q1 24 | — | -692.5% |
| Q4 25 | -24.9% | 65.7% | ||
| Q3 25 | 23.9% | -2572.2% | ||
| Q2 25 | -16.5% | -504.8% | ||
| Q1 25 | -5.1% | -2097.7% | ||
| Q4 24 | — | — | ||
| Q3 24 | -16.7% | -425.5% | ||
| Q2 24 | — | -1964.4% | ||
| Q1 24 | — | 29.9% |
| Q4 25 | $-0.19 | $0.25 | ||
| Q3 25 | $0.19 | $-0.17 | ||
| Q2 25 | $-0.16 | $-0.14 | ||
| Q1 25 | $-0.06 | $-0.11 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | $-0.06 | ||
| Q2 24 | — | $-0.30 | ||
| Q1 24 | — | $0.01 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $13.5M | $40.0M |
| Total DebtLower is stronger | $314.3M | — |
| Stockholders' EquityBook value | $391.2M | $49.4M |
| Total Assets | $854.4M | $59.0M |
| Debt / EquityLower = less leverage | 0.80× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $13.5M | $40.0M | ||
| Q3 25 | $19.6M | $37.9M | ||
| Q2 25 | $8.4M | $44.8M | ||
| Q1 25 | $3.3M | $40.6M | ||
| Q4 24 | — | $59.3M | ||
| Q3 24 | — | $68.8M | ||
| Q2 24 | — | $73.0M | ||
| Q1 24 | — | $80.2M |
| Q4 25 | $314.3M | — | ||
| Q3 25 | $307.1M | — | ||
| Q2 25 | $316.9M | — | ||
| Q1 25 | $310.2M | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $391.2M | $49.4M | ||
| Q3 25 | $385.2M | $36.4M | ||
| Q2 25 | $369.9M | $44.5M | ||
| Q1 25 | $324.7M | $50.5M | ||
| Q4 24 | — | $55.1M | ||
| Q3 24 | $1.0K | $58.5M | ||
| Q2 24 | — | $60.4M | ||
| Q1 24 | — | $74.1M |
| Q4 25 | $854.4M | $59.0M | ||
| Q3 25 | $846.8M | $51.1M | ||
| Q2 25 | $856.5M | $60.7M | ||
| Q1 25 | $860.8M | $67.9M | ||
| Q4 24 | — | $90.6M | ||
| Q3 24 | $1.0K | $99.0M | ||
| Q2 24 | — | $107.8M | ||
| Q1 24 | — | $118.3M |
| Q4 25 | 0.80× | — | ||
| Q3 25 | 0.80× | — | ||
| Q2 25 | 0.86× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $42.1M | $18.4M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | 1.50× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $42.1M | $18.4M | ||
| Q3 25 | $8.3M | $-8.7M | ||
| Q2 25 | $9.3M | $-7.5M | ||
| Q1 25 | $8.1M | $-7.5M | ||
| Q4 24 | — | $-24.0M | ||
| Q3 24 | — | $765.0K | ||
| Q2 24 | — | $-10.9M | ||
| Q1 24 | — | $-4.0M |
| Q4 25 | — | 1.50× | ||
| Q3 25 | 2.06× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -9.75× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FVR
Segment breakdown not available.
SCYX
| Glaxosmithkline Intellectual Property | $17.2M | 92% |
| Products | $1.4M | 8% |
